Journal article
Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas
SC Ng, S Plamondon, A Gupta, D Burling, MA Kamm
Alimentary Pharmacology and Therapeutics | WILEY | Published : 2009
Abstract
Background Anti-tumour necrosis factor (TNF) therapy effectively treats Crohn's perineal fistulas (CPF); the effect on health-related quality of life (HRQoL) remains unknown. Aims To evaluate the effect of anti-TNF therapy on the HRQoL of patients with CPF in daily clinical practice. Methods Prospective evaluation of clinical and magnetic resonance imaging (MRI) responses, disease activity (Perianal Disease Activity Index - PDAI), and HRQoL assessment [Inflammatory Bowel Disease Questionnaire (IBDQ)] in patients receiving anti-TNF therapy for CPF treated up to 12 months. Results In all, 26 patients with CPF were treated (mean age 39 years; 19 infliximab, 7 adalimumab). At baseline, 85% patie..
View full abstractGrants
Funding Acknowledgements
Declaration of personal interests: Michael Kamm has served as a speaker, a consultant and an advisory board member for Abott Centocor, Scherring Plough and UCB. Permission to use Inflammatory Bowel Disease Questionnaire in this study was obtained from McMaster University. Declaration of funding interests: This study was funded in part by Scherring-Plough UK with an unrestricted educational grant. Schering-Plough UK had no knowledge of the nature, content or results of the study.